1. Home
  2. FBIO vs SCLX Comparison

FBIO vs SCLX Comparison

Compare FBIO & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FBIO
  • SCLX
  • Stock Information
  • Founded
  • FBIO 2006
  • SCLX 2011
  • Country
  • FBIO United States
  • SCLX United States
  • Employees
  • FBIO N/A
  • SCLX N/A
  • Industry
  • FBIO Biotechnology: Pharmaceutical Preparations
  • SCLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FBIO Health Care
  • SCLX Health Care
  • Exchange
  • FBIO Nasdaq
  • SCLX Nasdaq
  • Market Cap
  • FBIO 44.0M
  • SCLX 51.3M
  • IPO Year
  • FBIO N/A
  • SCLX N/A
  • Fundamental
  • Price
  • FBIO $1.53
  • SCLX $6.02
  • Analyst Decision
  • FBIO Strong Buy
  • SCLX Strong Buy
  • Analyst Count
  • FBIO 3
  • SCLX 4
  • Target Price
  • FBIO $21.00
  • SCLX $11.33
  • AVG Volume (30 Days)
  • FBIO 247.1K
  • SCLX 68.9K
  • Earning Date
  • FBIO 05-14-2025
  • SCLX 05-12-2025
  • Dividend Yield
  • FBIO N/A
  • SCLX N/A
  • EPS Growth
  • FBIO N/A
  • SCLX N/A
  • EPS
  • FBIO N/A
  • SCLX N/A
  • Revenue
  • FBIO $57,675,000.00
  • SCLX $56,590,000.00
  • Revenue This Year
  • FBIO $63.20
  • SCLX $115.30
  • Revenue Next Year
  • FBIO $66.70
  • SCLX $73.33
  • P/E Ratio
  • FBIO N/A
  • SCLX N/A
  • Revenue Growth
  • FBIO N/A
  • SCLX 21.07
  • 52 Week Low
  • FBIO $1.33
  • SCLX $5.80
  • 52 Week High
  • FBIO $2.89
  • SCLX $80.50
  • Technical
  • Relative Strength Index (RSI)
  • FBIO 46.68
  • SCLX 30.63
  • Support Level
  • FBIO $1.45
  • SCLX $6.13
  • Resistance Level
  • FBIO $1.64
  • SCLX $7.64
  • Average True Range (ATR)
  • FBIO 0.13
  • SCLX 1.42
  • MACD
  • FBIO 0.00
  • SCLX -0.21
  • Stochastic Oscillator
  • FBIO 64.52
  • SCLX 3.80

About FBIO Fortress Biotech Inc.

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: